Pasar al contenido principal
U.S. flag

Un sitio oficial del Gobierno de Estados Unidos

Así es como usted puede verificarlo

Dot gov
Los sitios web oficiales usan .gov
Un sitio web .gov pertenece a una organización oficial del Gobierno de Estados Unidos.
Https

Los sitios web seguros .gov usan HTTPS
Un candado ( Candado Un candado cerrado ) o https:// significa que usted se conectó de forma segura a un sitio web .gov. Comparta información sensible sólo en sitios web oficiales y seguros.

  • Quiénes somos
    • Sobre la DEA
    • Mission
    • Nuestra historia
    • DEA Museum
    • Divisiones operativas
      • División de Aviación
    • Wall of Honor
    • Contáctenos
      • Submit a Tip
      • Extortion Scam
      • Public Affairs
      • Social Media Directory
  • Recursos
    • Recovery Resources
    • Data and Statistics
      • Domestic Arrests
      • Staffing and Budget
    • Ley de Libertad de Información
      • About FOIA
      • Contact DEA FOIA
      • Make a Request
      • What Happens After Making a Request
      • Requester Categories
      • Fees Charged
      • Fee Waiver
      • FOIA FAQ
      • FOIA Logs and Reports
      • FOIA Library
      • Additional FOIA Links
      • FOIA Exemptions
      • What Are Exclusions?
      • Privacy Act
      • Privacy Act Exemptions
      • Privacy Impact Assessment and Management Information Systems
    • Publications
    • Galerías Multimedia
    • Programa de Asistencia a Testigos para Víctimas
      • Victim Witness Assistance Program Resources

United States Drug Enforcement Administration

  • Recibir Actualizaciones
  • Scam Alert
  • Menú Completo
  • English
  • Español

Main Menu

  • Quiénes somos
    • Sobre la DEA
    • Mission
    • Nuestra historia
    • DEA Museum
    • Divisiones operativas
    • Wall of Honor
    • Contáctenos
  • Recursos
    • Recovery Resources
    • Data and Statistics
    • Ley de Libertad de Información
    • Publications
    • Galerías Multimedia
    • Programa de Asistencia a Testigos para Víctimas

Drug Enforcement Administration

Daniel J. Kafafian, Acting Special Agent in Charge
New Jersey
@DEANewJerseyDiv
Noviembre 04, 2021
Contact: Kenneth M. Heino
Phone Number: (571) 362-6616
For Immediate Release

Doctor Charged With Accepting Bribes in Exchange for Fentanyl

NEWARK, N.J. – Special Agent in Charge of the Drug Enforcement Administration’s New Jersey Division Susan A. Gibson and Acting U.S. Attorney for the District of New Jersey Rachael A. Honig announced a Monmouth County, New Jersey, doctor was charged today for his participation in a scheme to receive bribes and kickbacks from a pharmaceutical company in exchange for unlawfully prescribing large volumes of a powerful fentanyl narcotic.

Mukaram Gazi, 51, of Marlboro, New Jersey, is charged by indictment with one count of conspiracy to pay and receive kickbacks; one count of receiving kickbacks; one count of health care fraud; and one count of conspiring to unlawfully distribute dangerous narcotics.

Gazi owned and maintained a urology practice with locations in Freehold, Hamilton, Howell, and Toms River, New Jersey. Gazi solicited and received more than $130,000 in bribes and kickbacks from Insys Therapeutics, a pharmaceutical company based in Arizona, in exchange for prescribing its drug Subsys, a powerful opioid narcotic designed to rapidly enter a patient’s bloodstream upon being sprayed under the tongue. The U.S. Food and Drug Administration approved Subsys solely for the “management of breakthrough pain in cancer patients who are already receiving and who are tolerant to around the clock therapy for their underlying persistent cancer pain.”

Gazi did not treat patients who were suffering from breakthrough cancer pain and was not in the practice of prescribing fentanyl-based pain medications. However, in exchange for bribes and kickbacks from Insys Therapeutics, he began prescribing Subsys to a number of patients for whom Subsys was medically unnecessary.

The bribes and kickbacks Gazi accepted for prescribing Subsys were disguised as payments for educational presentations regarding Subsys that Gazi purportedly provided to licensed practitioners. In reality, these presentations were a sham – they often functioned as social events at restaurants, lacked the appropriate audience of licensed practitioners who could prescribe Subsys, and many of the purported signatures on the speaker program sign-in sheets were forged. Gazi also prescribed high-dosage Adderall to a pharmacy owner who filled many of his Subsys prescriptions, as well as the pharmacy owner’s significant other, to induce the pharmacy owner to continue filling his Subsys prescriptions.

Gazi also caused the submission of fraudulent claims to Medicare, New Jersey Medicaid, and other health insurance providers for the prescriptions of Subsys and Adderall that he wrote, which were induced through kickbacks, medically unnecessary, and not eligible for reimbursement. He also conspired with others to distribute these powerful narcotics outside the usual course of professional practice and not for a legitimate medical purpose.

Acting U.S. Attorney Honig credited special agents the U.S. Drug Enforcement Administration, under the direction of Special Agent in Charge Susan A. Gibson in Newark; special agents and investigators of the FBI, under the direction of Special Agent in Charge George M. Crouch Jr. in Newark; special agents of the Department of Health and Human Services – Office of Inspector General, under the direction of Special Agent in Charge Scott J. Lampert; and special agents of the U.S. Attorney’s Office, under the direction of Special Agent in Charge Thomas Mahoney, with the investigation leading to today’s indictment.

21-68                                                               ###

SAMHSA Behavioral Health Treatment Locator

  • Quienes Somos
    • Sobre
    • Contáctenos
    • Museo DEA
  • Recursos
    • Programa de Asistencia al Empleado
    • Empleador con Igualdad de Oportunidades
    • Ley de Libertad de Información (FOIA)
    • Publicaciones
    • Galerías Multimedia
    • Programa de Asistencia a Testigos para Víctimas
  • Hacer Negocios
    con la DEA
    • Resumen
    • Proveedores Actuales
    • Futuros Vendedores
    • Cláusulas de Seguridad
    • Formularios de Seguridad
    • Programa de Pequeñas Empresas
  • Políticas
    • Accesibilidad, Complementos y Política
    • Políticas Legales y Descargos de Responsabilidad
    • Antidiscriminación y Represalias Acto
    • Política de Privacidad
    • Política de Igualdad de Oportunidades en el Empleo del U.S. DOJ
    • USA.gov
    • Protección de Denunciantes
Inicio

United States Drug Enforcement Administration

DEA.gov is an official site of the U.S. Department of Justice
Facebook Twitter LinkedIn Instagram

DEA Contact Center

(202) 307-1000 info@dea.gov
Contact the Webmaster